(Q34539222)

2 August 2017

title

Ancestral and consensus envelope immunogens for HIV-1 subtype C. (English)

1 reference

2 August 2017

1 reference

2 August 2017

Frederic Bibollet-Ruche

object named as

Frederic Bibollet-Ruche

0 references

Beatrice H Hahn

0 references

Barton F Haynes

1 reference

2 August 2017

George M Shaw

1 reference

2 August 2017

Kenneth P Zammit

1 reference

2 August 2017

Denise L Kothe

1 reference

2 August 2017

Yalu Chen

1 reference

2 August 2017

Yingying Li

1 reference

2 August 2017

Julie M Decker

1 reference

2 August 2017

Maria G Salazar

1 reference

2 August 2017

Zhiping Weng

1 reference

2 August 2017

Eric A Weaver

1 reference

2 August 2017

Feng Gao

1 reference

2 August 2017

language of work or name

English

0 references

publication date

14 June 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

352

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

438-449

1 reference

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

The rational design of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Prospects for an AIDS vaccine: three big questions, no easy answers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Diversity considerations in HIV-1 vaccine selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Immunogen sequence: the fourth tier of AIDS vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Consensus and Ancestral State HIV Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Progress towards an HIV-1 subtype C vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Estimated Global Distribution and Regional Spread of HIV-1 Genetic Subtypes in the Year 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.05.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2006.05.011

1 reference

release_mlt2drujs5h37nlubmxmkd5esy

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mlt2drujs5h37nlubmxmkd5esy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference